Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trimetazidine - Martin Pharmaceuticals

Next Previous
Search
Drug Profile

Trimetazidine - Martin Pharmaceuticals

Alternative Names: LIVANTRA

Latest Information Update: 03 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Martin Pharmaceuticals
  • Class Anti-ischaemics; Cytoprotectives; Hepatoprotectants; Ischaemic heart disorder therapies; Piperazines; Small molecules; Vasodilators
  • Mechanism of Action Adenosine triphosphatase inhibitors; Calcium channel antagonists; Free radical scavengers; Platelet aggregation inhibitors; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Liver failure
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pulmonary arterial hypertension
  • No development reported Liver failure

Most Recent Events

  • 03 Sep 2024 Preclinical trials in Pulmonary arterial hypertension in USA (unspecified route) prior to September 2024 (Martin Pharmaceuticals pipeline, September 2024)
  • 03 Sep 2024 Pharmacodynamics data from preclinical studies in Pulmonary arterial hypertension were released by Martin Pharmaceuticals, prior to September 2024 (Martin Pharmaceuticals pipeline, September 2024)
  • 28 Dec 2021 No recent reports of development identified for phase-I development in Liver-failure in Austria (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top